FR15C0079I2 - Expression optimisee de hpv 31 l1 dans la levure - Google Patents

Expression optimisee de hpv 31 l1 dans la levure

Info

Publication number
FR15C0079I2
FR15C0079I2 FR15C0079C FR15C0079C FR15C0079I2 FR 15C0079 I2 FR15C0079 I2 FR 15C0079I2 FR 15C0079 C FR15C0079 C FR 15C0079C FR 15C0079 C FR15C0079 C FR 15C0079C FR 15C0079 I2 FR15C0079 I2 FR 15C0079I2
Authority
FR
France
Prior art keywords
hpv31
yeast
polynucleotides
synthetic
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0079C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of FR15C0079I1 publication Critical patent/FR15C0079I1/fr
Application granted granted Critical
Publication of FR15C0079I2 publication Critical patent/FR15C0079I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR15C0079C 2003-03-24 2015-12-04 Expression optimisee de hpv 31 l1 dans la levure Active FR15C0079I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45717203P 2003-03-24 2003-03-24
PCT/US2004/008677 WO2004084831A2 (fr) 2003-03-24 2004-03-19 Expression optimisee de hpv 31 l1 dans la levure

Publications (2)

Publication Number Publication Date
FR15C0079I1 FR15C0079I1 (fr) 2016-08-01
FR15C0079I2 true FR15C0079I2 (fr) 2016-11-25

Family

ID=33098208

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0079C Active FR15C0079I2 (fr) 2003-03-24 2015-12-04 Expression optimisee de hpv 31 l1 dans la levure

Country Status (21)

Country Link
US (2) US7276243B2 (fr)
EP (1) EP1608767B1 (fr)
JP (1) JP4505452B2 (fr)
KR (1) KR101080628B1 (fr)
CN (1) CN100506999C (fr)
AT (1) ATE546529T1 (fr)
AU (1) AU2004224335B2 (fr)
BR (1) BRPI0408639B8 (fr)
CA (1) CA2519112C (fr)
EC (1) ECSP056032A (fr)
ES (1) ES2381964T3 (fr)
FR (1) FR15C0079I2 (fr)
IL (1) IL171067A (fr)
IS (1) IS2859B (fr)
MX (1) MXPA05010285A (fr)
NL (1) NL300772I1 (fr)
NO (3) NO341527B1 (fr)
NZ (1) NZ542246A (fr)
RU (1) RU2356943C2 (fr)
WO (1) WO2004084831A2 (fr)
ZA (1) ZA200507178B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
BRPI0509079B8 (pt) * 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
JP4769247B2 (ja) * 2004-06-18 2011-09-07 インディアン・イムノロジカルズ・リミテッド ヒトパピローマウイルス１６型に対するＳａｌｍｏｎｅｌｌａワクチン株に関するコドン最適化されたＨＰＶ１６Ｌ１
JP2006262846A (ja) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk 酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース
JP2008538922A (ja) * 2005-04-28 2008-11-13 メルク エンド カムパニー インコーポレーテッド 蛍光多重ｈｐｖｐｃｒアッセイ
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
CN101622008A (zh) * 2007-03-09 2010-01-06 默克公司 乳头瘤病毒疫苗组合物
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
EP2479187A1 (fr) 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Gènes codant pour la protéine majeure de capside L1 du virus du papillome humain
US20110201086A1 (en) 2010-02-12 2011-08-18 Otsuka Pharmaceutical Co., Ltd. Method for producing recombinant virus
CA2799205A1 (fr) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Analyse de capture hybride a resultats rapides et sondes associees tronquees de maniere strategique
KR102049988B1 (ko) 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN107916234A (zh) * 2012-03-28 2018-04-17 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv6 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
CN112280793B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (fr) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Procédé d'obtention de formulations de vaccin séchées thermostables
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
WO2016057954A2 (fr) * 2014-10-10 2016-04-14 Board Of Regents Of The University Of Texas System Terminateurs exogènes pour contrôler l'expression génique fongique
RU2677336C2 (ru) * 2014-12-26 2019-01-16 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
CN106148359A (zh) * 2015-03-30 2016-11-23 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106831961B (zh) * 2015-12-04 2019-11-05 厦门大学 一种人乳头瘤病毒58型l1蛋白的突变体
WO2021013062A1 (fr) * 2019-07-19 2021-01-28 神州细胞工程有限公司 Protéine l1 de papillomavirus humain de type 31 chimérique
BR112022015313A2 (pt) 2020-02-14 2022-09-27 Merck Sharp & Dohme Llc Vacina de hpv
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
CA3229064A1 (fr) 2021-08-19 2023-02-23 Andrew Bett Nanoparticule lipidique thermostable et ses methodes d'utilisation
WO2024183665A1 (fr) * 2023-03-07 2024-09-12 北京康乐卫士生物技术股份有限公司 Vaccin contre le papillomavirus humain et son utilisation
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物
US20250281594A1 (en) * 2024-03-11 2025-09-11 Sk Bioscience Co., Ltd. Truncated recombinant l1 protein of human papillomavirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
CA2280195A1 (fr) 1997-02-07 1998-08-13 Merck & Co., Inc. Genes synthetiques du gag hiv
EP1002091B1 (fr) 1997-07-09 2012-02-29 Coridon Pty Limited Sequence d'acides nucleiques et procede pour exprimer, de maniere selective, une proteine dans une cellule ou un tissu cible
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
FR2768748B1 (fr) * 1997-09-24 2001-06-08 Rhone Poulenc Agrochimie Recodage de sequences d'adn permettant leur expression dans les levures et levures transformees obtenues
CA2339324C (fr) * 1998-08-14 2011-05-31 Robert S. Lowe Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
ATE346947T1 (de) 2000-07-21 2006-12-15 Glaxo Group Ltd Kodon-optimierte papillomavirussequenzen
AU2001267896A1 (en) 2000-07-26 2002-02-05 Shinko Pantec Co., Ltd. Hydrogen/oxygen supply system
US7041500B2 (en) * 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
NO20054889D0 (no) 2005-10-21
RU2356943C2 (ru) 2009-05-27
NO20054889L (no) 2005-12-19
US20080166371A1 (en) 2008-07-10
JP4505452B2 (ja) 2010-07-21
CA2519112C (fr) 2012-09-11
NL300772I2 (fr) 2015-12-29
US7276243B2 (en) 2007-10-02
KR101080628B1 (ko) 2011-11-08
NL300772I1 (fr) 2015-12-29
BRPI0408639A (pt) 2006-03-28
NO341527B1 (no) 2017-12-04
NO2018010I1 (no) 2018-03-27
NO2022053I1 (no) 2022-11-30
KR20050119141A (ko) 2005-12-20
IS2859B (is) 2013-12-15
EP1608767B1 (fr) 2012-02-22
HK1090953A1 (zh) 2007-01-05
ECSP056032A (es) 2006-01-27
ZA200507178B (en) 2006-08-30
BRPI0408639B8 (pt) 2021-05-25
US20060177817A1 (en) 2006-08-10
IS8019A (is) 2005-09-12
FR15C0079I1 (fr) 2016-08-01
WO2004084831A3 (fr) 2004-11-11
EP1608767A4 (fr) 2006-08-30
RU2005132603A (ru) 2006-04-27
IL171067A (en) 2011-11-30
ES2381964T3 (es) 2012-06-04
CN1761759A (zh) 2006-04-19
BRPI0408639B1 (pt) 2020-08-18
NZ542246A (en) 2007-12-21
MXPA05010285A (es) 2005-11-17
AU2004224335A1 (en) 2004-10-07
EP1608767A2 (fr) 2005-12-28
ATE546529T1 (de) 2012-03-15
WO2004084831A2 (fr) 2004-10-07
AU2004224335B2 (en) 2010-01-28
JP2006523099A (ja) 2006-10-12
CN100506999C (zh) 2009-07-01
CA2519112A1 (fr) 2004-10-07
US7482428B2 (en) 2009-01-27

Similar Documents

Publication Publication Date Title
NO2018010I1 (no) HPV 31 L1 protein
EP1687329B8 (fr) Expression optimisee de hpv 58 l1 dans de la levure
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
TW200602490A (en) Optimized expression of HPV 52 L1 in yeast
WO2003077942A3 (fr) Antigenes viraux
PT1212358E (pt) Genes sinteticos de papilomavirus humano
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
EP2589604A4 (fr) Protéine l1 tronquée du papillomavirus humain de type 52
WO1999061052A3 (fr) Immunisation par voie orale au moyen de particules de type viral du papillomavirus
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
EP1427443A4 (fr) Vaccin mettant en oeuvre des proteines e du virus du papillome administrees par vecteur viral
MY138895A (en) Optimized expression of hpv 31 l1 in yeast
TH82139B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
AR045249A1 (es) Expresion optimizada de hpv 31 l1 en levadura
EA200702077A1 (ru) Вакцина
WO2003090664A3 (fr) Polypeptide hpv-16 e7 mute, preparations pharmaceutiques le contenant, et son procede de preparation